Literature DB >> 20869920

Treatment initiation in epilepsy: an expert consensus in Spain.

V Villanueva1, J C Sánchez-Álvarez, P Peña, J Salas- Puig, F Caballero-Martínez, A Gil-Nagel.   

Abstract

OBJECTIVE: The goals of this study were to explore the diverse criteria surrounding indications for antiepileptic therapy and to establish a consensus on drug selection for initial monotherapy in adult patients with epilepsy.
METHODS: The study was performed using the modified Delphi method, which aims to achieve professional consensus by means of a series of questionnaires. Three different groups of items were evaluated: the beginning of antiepileptic treatment, the drug selected for initial monotherapy with respect to the type of epilepsy, and the drug selected for initial monotherapy with respect to comorbidity.
RESULTS: Sixty experts completed two rounds of a questionnaire. In the first round, consensus was reached on 135 of the 194 questions analyzed. After the second round, consensus was reached on 148 items. The main findings of the survey revealed a consensus on beginning treatment after the first seizure when the EEG showed abnormalities such as generalized spike-wave discharges, when MRI demonstrated an epileptogenic brain lesion, and in elderly patients. Regarding to the antiepileptic drug selected for initial monotherapy with respect to type of epilepsy, levetiracetam and lamotrigine were recommended for generalized tonic-clonic seizures regardless of sex or age; levetiracetam was recommended for myoclonic epilepsy regardless of sex; valproic acid, ethosuximide, levetiracetam, and lamotrigine were chosen for absence epilepsy; and carbamazepine, levetiracetam, lamotrigine, and oxcarbazepine were recommended for partial epilepsy regardless of age or sex. Finally, in the evaluation of drug selection with respect to comorbidity, first-generation drugs were less recommended than second-generation drugs, which were clearly preferable. The drugs on which there was a greater consensus were levetiracetam, lamotrigine, valproic acid, and topiramate.
CONCLUSIONS: There is a tendency to begin treatment after the first seizure, depending on the results of additional testing. In general, first-generation drugs are less recommended for different types of epilepsy, especially in the presence of a comorbid condition. However, the authors are conveying perceptions and opinions, the effect of which on treatment outcomes has not been evaluated.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20869920     DOI: 10.1016/j.yebeh.2010.07.016

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  4 in total

1.  Effects of an acute seizure on associative learning and memory.

Authors:  Andrew J Holley; Joaquin N Lugo
Journal:  Epilepsy Behav       Date:  2015-12-03       Impact factor: 2.937

Review 2.  A systematic review and meta-analysis of anti-epileptic medication non-adherence among people with epilepsy in Ethiopia.

Authors:  Zelalem Belayneh; Birhanie Mekuriaw
Journal:  Arch Public Health       Date:  2020-05-01

3.  A Latin American, Portuguese and Spanish consensus on a core communication curriculum for undergraduate medical education.

Authors:  Cristina García de Leonardo; Roger Ruiz-Moral; Fernando Caballero; Afonso Cavaco; Philippa Moore; Lila Paula Dupuy; Antonio Pithon-Cyrino; Ma Teresa Cortés; Marilen Gorostegui; Elizabete Loureiro; Josep Ma Bosch Fontcuberta; Luis Casasbuenas Duarte; Lara Kretzer; Emilia Arrighi; Albert Jovell
Journal:  BMC Med Educ       Date:  2016-03-28       Impact factor: 2.463

4.  Effect of Training on Visual Identification of High Frequency Oscillations-A Delphi-Style Intervention.

Authors:  Aaron M Spring; Daniel J Pittman; Arsalan Rizwan; Yahya Aghakhani; Jeffrey Jirsch; Mary Connolly; Samuel Wiebe; Juan Pablo Appendino; Anita Datta; Trevor Steve; Neelan Pillay; Manouchehr Javidan; Morris Scantlebury; Chantelle Hrazdil; Colin Bruce Josephson; Cyrus Boelman; Donald Gross; Shaily Singh; Luis Bello-Espinosa; Linda Huh; Nathalie Jetté; Paolo Federico
Journal:  Front Neurol       Date:  2022-02-14       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.